The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.

BACKGROUND Endothelin is a powerful vasoconstrictor peptide derived from the endothelium. We evaluated the contribution of endothelin to blood-pressure regulation in patients with essential hypertension by studying the effect of an endothelin-receptor antagonist, bosentan. METHODS We studied 293 patients with mild-to-moderate essential hypertension. After a placebo run-in period of four to six weeks, patients were randomly assigned to receive one of four oral doses of bosentan (100, 500, or 1000 mg once daily or 1000 mg twice daily), placebo, or the angiotensin-converting-enzyme inhibitor enalapril (20 mg once daily) for four weeks. Blood pressure was measured before and after treatment. RESULTS As compared with placebo, bosentan resulted in a significant reduction in diastolic pressure with a daily dose of 500 or 2000 mg (an absolute reduction of 5.7 mm Hg at each dose), which was similar to the reduction with enalapril (5.8 mm Hg). There were no significant changes in heart rate. Bosentan did not result in activation of the sympathetic nervous system (as determined by measurement of the plasma norepinephrine level) or the renin-angiotensin system (as determined by measurements of plasma renin activity and angiotensin II levels). CONCLUSIONS An endothelin-receptor antagonist, bosentan, significantly lowered blood pressure in patients with essential hypertension, suggesting that endothelin may contribute to elevated blood pressure in such patients. The favorable effect of treatment with bosentan on blood pressure occurred without reflexive neurohormonal activation.

[1]  G. Hopfgartner,et al.  Pharmacokinetics and pharmacodynamics of the endothelin‐receptor antagonist bosentan in healthy human subjects , 1996, Clinical pharmacology and therapeutics.

[2]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[3]  B. Löffler,et al.  Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). , 1994, Circulation.

[4]  W. Neidhart,et al.  Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. , 1994, The Journal of pharmacology and experimental therapeutics.

[5]  B. Löffler,et al.  Radioimmunological Determination of Endothelin Peptides in Human Plasma: A Methodological Approach , 1994 .

[6]  W. Neidhart,et al.  Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist , 1993, Nature.

[7]  D. Webb,et al.  The endothelin family of peptides: local hormones with diverse roles in health and disease? , 1993, Clinical science.

[8]  D. Webb,et al.  Endothelium-dependent modulation of responses to endothelin-I in human veins. , 1993, Clinical science.

[9]  M. Yano,et al.  Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. , 1993, Life sciences.

[10]  M. J. Sumner,et al.  Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction , 1992, British journal of pharmacology.

[11]  J. McMurray,et al.  Plasma Endothelin in Chronic Heart Failure , 1992, Circulation.

[12]  P Bauer,et al.  Multiple testing in clinical trials. , 1991, Statistics in medicine.

[13]  S. Nakanishi,et al.  Cloning and expression of a cDNA encoding an endothelin receptor , 1990, Nature.

[14]  T. Sakurai,et al.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor , 1990, Nature.

[15]  H. Yasuda,et al.  Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. , 1990, Journal of molecular and cellular cardiology.

[16]  T. Horio,et al.  Plasma immunoreactive endothelin in essential hypertension. , 1990, The American journal of medicine.

[17]  K. Nakao,et al.  Increased plasma endothelin level in patients with essential hypertension. , 1990, The New England journal of medicine.

[18]  M. Boarder,et al.  Characterization of Endothelin‐1 Stimulation of Catecholamine Release from Adrenal Chromaffin Cells , 1989, Journal of cardiovascular pharmacology.

[19]  M. Redfield,et al.  Integrated cardiac, renal, and endocrine actions of endothelin. , 1989, The Journal of clinical investigation.

[20]  S. R. Searle,et al.  Linear Models For Unbalanced Data , 1988 .

[21]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[22]  A. Kappelgaard,et al.  Measurement of angiotensin II in human plasma: technical modifications and practical experience. , 1976, Clinica chimica acta; international journal of clinical chemistry.